TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36695397

Group type: EXPERIMENTAL
Intervention: Computed tomography pulmonary angiography (CTPA)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Low clinical probability and normal D-dimer
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Patients without other findings suspicious for PE
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Patients with findings suspicious for PE
Number of subjects: 417
Study: 36695416

Group type: EXPERIMENTAL
Intervention: upright-backward
Number of subjects: 32

Group type: COMPARATOR
Intervention: upright-forward
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: wheelie-forward
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: wheelie-backward
Number of subjects: 32
Study: 36695483

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 11218
Study: 36695625

Group type: EXPERIMENTAL
Intervention: ATG monotherapy (6 or 3 mg/kg body weight) without concomitant immunosuppression
Number of subjects: 6
Study: 36695682

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (100,000 IU every 2 weeks for 2 months, then monthly for 22 months)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Low-dose cholecalciferol (12,000 IU every 2 weeks for 2 months, then monthly for 22 months)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol
Number of subjects: 536

Group type: COMPARATOR
Intervention: Low-dose cholecalciferol
Number of subjects: 536
Study: 36695790

Group type: EXPERIMENTAL
Intervention: Peeled internal limiting membrane reposition
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional internal limiting membrane peeling
Number of subjects: 27
Study: 36695802

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Metamorphopsia (M-CHARTS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Aniseikonia (New Aniseikonia Test)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Outer retinal fold
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Outer retinal reflectivity
Number of subjects: 38
Study: 36695965

Group type: EXPERIMENTAL
Intervention: Crown lengthening surgery (CLS)
Number of subjects: 18
Study: 36696167

Group type: EXPERIMENTAL
Intervention: Pictograms
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no pictograms)
Number of subjects: 57
Study: 36696168

Group type: EXPERIMENTAL
Intervention: Mixed intervention (face-to-face-digital) with a checklist integrated into the clinical workflow.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 22
Study: 36696172

Group type: EXPERIMENTAL
Intervention: Accurate step count
Number of subjects: 117

Group type: COMPARATOR
Intervention: Deflated step count
Number of subjects: 117

Group type: COMPARATOR
Intervention: Inflated step count
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Accurate step count + meta-mindset intervention
Number of subjects: 117
Study: 36696206

Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control (no caplacizumab)
Number of subjects: 232
Study: 36696215

Group type: EXPERIMENTAL
Intervention: individual factor VIII concentrates
Number of subjects: 1076
Study: 36696330

Group type: EXPERIMENTAL
Intervention: LYMPHA
Number of subjects: 45

Group type: COMPARATOR
Intervention: non-LYMPHA
Number of subjects: 45
Study: 36696540

Group type: EXPERIMENTAL
Intervention: ibrutinib plus R-CHOP
Number of subjects: 766

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 766
Study: 36696639

Group type: EXPERIMENTAL
Intervention: DHEA-S
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: FSH
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: WMH
Number of subjects: 79
Study: 36696822

Group type: EXPERIMENTAL
Intervention: 4-meter walk test (4-MWT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 10-meter walk test (10-MWT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 times sit-to-stand test (5TSTS)
Number of subjects: 36
Study: 36696827

Group type: EXPERIMENTAL
Intervention: Shorter antimicrobial treatment (≤10 days)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Longer antimicrobial treatment (>10 days)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Overall median duration of antibiotic therapy
Number of subjects: 382
Study: 36696826

Group type: EXPERIMENTAL
Intervention: Infants with 'Never recovered' growth trajectory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants with 'Partially recovered' growth trajectory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parents with low dyadic adjustment and infants with 'Partially recovered' growth trajectory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parents with high dyadic adjustment and infants with 'Never recovered' growth trajectory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of partner relationship
Number of subjects: 0
Study: 36696843

Group type: EXPERIMENTAL
Intervention: Self-report of drug use
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Self-report of drug use among those with positive opioid UDS
Number of subjects: 295

Group type: COMPARATOR
Intervention: Treatment type
Number of subjects: 295
Study: 36696980

Group type: EXPERIMENTAL
Intervention: Simple hysterectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified radical hysterectomy (Querleu-Morrow type B2)
Number of subjects: 40
Study: 36696990

Group type: EXPERIMENTAL
Intervention: Favourable lifestyle group (4-6 healthy lifestyle factors)
Number of subjects: 29072

Group type: EXPERIMENTAL
Intervention: Average lifestyle group (2-3 healthy lifestyle factors)
Number of subjects: 29072

Group type: EXPERIMENTAL
Intervention: Favourable lifestyle group (non-APOE ε4 carriers)
Number of subjects: 29072

Group type: EXPERIMENTAL
Intervention: Average lifestyle group (non-APOE ε4 carriers)
Number of subjects: 29072

Group type: COMPARATOR
Intervention: APOE ε4 status and lifestyle profiles
Number of subjects: 29072
Study: 36697048

Group type: EXPERIMENTAL
Intervention: Behavioural economics-based incentives and text messages to support medication adherence
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 36697050

Group type: EXPERIMENTAL
Intervention: Language-supported group antenatal care (gANC)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard antenatal care (sANC)
Number of subjects: 145
Study: 36697053

Group type: EXPERIMENTAL
Intervention: VR-BF (biofeedback-based virtual reality) using the ForeVR VR platform to engage breathing in gamified VR applications.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group using a pain reflection app.
Number of subjects: 70
Study: 36697134

Group type: EXPERIMENTAL
Intervention: Somatostatin receptor 2 (SST2) PET/MR imaging
Number of subjects: 61
Study: 36697156

Group type: EXPERIMENTAL
Intervention: In-hospital persistent AKI
Number of subjects: 8201

Group type: EXPERIMENTAL
Intervention: Transient AKI
Number of subjects: 8201

Group type: COMPARATOR
Intervention: No AKI
Number of subjects: 8201
Study: 36697158

Group type: EXPERIMENTAL
Intervention: Initial invasive strategy
Number of subjects: 777

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 777
Study: 36697204

Group type: EXPERIMENTAL
Intervention: Amulet occluder (dual occlusive mechanism device)
Number of subjects: 1788

Group type: COMPARATOR
Intervention: Watchman device (single occlusive mechanism device)
Number of subjects: 1788

Group type: EXPERIMENTAL
Intervention: Patients with DRT
Number of subjects: 1788
Study: 36697207

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 75 mg + nucleos(t)ide analogue (NA)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 250 mg + nucleos(t)ide analogue (NA)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo + nucleos(t)ide analogue (NA)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 + nucleos(t)ide analogue (NA)
Number of subjects: 232
Study: 36697215

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (MR) consisting of a diagnostic multidisciplinary consultation and eight sessions of physical and occupational therapy.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 47
Study: 36697272

Group type: EXPERIMENTAL
Intervention: Orientation group (n=57)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (n=57)
Number of subjects: 114
Study: 36697317

Group type: EXPERIMENTAL
Intervention: Ipatasertib plus abiraterone
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Placebo plus abiraterone
Number of subjects: 1097
Study: 36697694

Group type: EXPERIMENTAL
Intervention: Treatment of maternal periodontal disease during pregnancy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group (treatment after pregnancy)
Number of subjects: 306
Study: 36697840

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis DN-173010 containing yogurt
Number of subjects: 30

Group type: COMPARATOR
Intervention: Natural yogurt
Number of subjects: 30
Study: 36697929

Group type: EXPERIMENTAL
Intervention: Mi Puente (MP)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 536
Study: 36698062

Group type: EXPERIMENTAL
Intervention: 24-h ambulatory BP monitoring (ABPM)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Home BP monitoring (HBPM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clinic-based monitoring
Number of subjects: 27

Group type: COMPARATOR
Intervention: BP kiosk in clinics or pharmacies
Number of subjects: 27
Study: 36698064

Group type: EXPERIMENTAL
Intervention: Longitudinal data from 35 variables collected over 6 exam visits for 15 years
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Longitudinal data
Number of subjects: 3539
Study: 36698093

Group type: EXPERIMENTAL
Intervention: Standardised child records with increased psychosocial focus
Number of subjects: 12
Study: 36698135

Group type: EXPERIMENTAL
Intervention: High neutralizing antibody (NAb) titers at days 37, 97, and 187 after symptom onset
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Peak viral load during admission
Number of subjects: 47
Study: 36698168

Group type: EXPERIMENTAL
Intervention: Home-based tablet-based BCI intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clinic-based tablet-based BCI intervention
Number of subjects: 20
Study: 36698174

Group type: EXPERIMENTAL
Intervention: TCU© intervention (seven sessions over 2 months via Zoom)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SUPPORT© control condition (three sessions over 2 months via Zoom)
Number of subjects: 60
Study: 36698194

Group type: EXPERIMENTAL
Intervention: Tobacco cessation pharmacotherapy (varenicline) paired with behavioral support
Number of subjects: 208
Study: 36698197

Group type: EXPERIMENTAL
Intervention: blended therapist-assisted eMBCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: unguided individual eMBCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 0
Study: 36698207

Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alvopem)
Number of subjects: 199
Study: 36698210

Group type: EXPERIMENTAL
Intervention: Chess-based cognitive remediation training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Implicit computer-based habit-modifying training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard smoking cessation group therapy
Number of subjects: 90
Study: 36698416

Group type: EXPERIMENTAL
Intervention: PET/CT evaluation
Number of subjects: 61
Study: 36698447

Group type: EXPERIMENTAL
Intervention: Cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and lipohydroxy acid 0.05%
Number of subjects: 51
Study: 36698741

Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMAs) every 3 months over a 12-month study period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMAs)
Number of subjects: 20
Study: 36698743

Group type: EXPERIMENTAL
Intervention: Nurse AMIE for Echo Show (6 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nurse AMIE for Echo Show (3 months after a 3 month delay)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nurse AMIE for Echo Show
Number of subjects: 42
Study: 36698795

Group type: EXPERIMENTAL
Intervention: Self-care and lifestyle interventions (spending time in nature)
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Mental/emotional state assessment
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Well-being assessment (WHO-5)
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Self-efficacy assessment (GSE-3)
Number of subjects: 1138
Study: 36698862

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) combined with sound stimulation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) alone
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sound stimulation alone
Number of subjects: 87
Study: 36698880

Group type: EXPERIMENTAL
Intervention: Polyflow module of the Ansys software
Number of subjects: 45
Study: 36699018

Group type: EXPERIMENTAL
Intervention: Women with PCOS and central obesity
Number of subjects: 166

Group type: COMPARATOR
Intervention: Women without PCOS
Number of subjects: 166
Study: 36699304

Group type: EXPERIMENTAL
Intervention: Physiological-based deferred cord clamping (PBCC) after the onset of stable regular breathing
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard time-based cord clamping < 1 minute (control group)
Number of subjects: 71
Study: 36699521

Group type: EXPERIMENTAL
Intervention: Resting-state functional MRI (rs-fMRI) metrics including fractional amplitude of low-frequency fluctuation (fALFF), regional homogeneity (ReHo), degree centrality (DC), voxel-mirrored homotopic connectivity (VMHC), functional connectivity strength (FCS), and seed-based FC.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 100
Study: 36699896

Group type: EXPERIMENTAL
Intervention: Stop Sexual Harassment intervention
Number of subjects: 0
Study: 36700062

Group type: EXPERIMENTAL
Intervention: BELA+EVL
Number of subjects: 68

Group type: COMPARATOR
Intervention: TAC+MMF
Number of subjects: 68
Study: 36700361

Group type: EXPERIMENTAL
Intervention: Virtual Tour Group (VT+)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-virtual Tour Group (VT-)
Number of subjects: 125
Study: 36700391

Group type: EXPERIMENTAL
Intervention: Diabetes Staging System (DSS)
Number of subjects: 0
Study: 36700426

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 6264

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in patients with QRS ≥150 ms and LBBB
Number of subjects: 6264

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in patients with QRS ≥150 ms and IVCD
Number of subjects: 6264

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) in patients with RBBB
Number of subjects: 6264
Study: 36700518

Group type: EXPERIMENTAL
Intervention: hIVIG prepared from humans
Number of subjects: 947

Group type: COMPARATOR
Intervention: hIVIG
Number of subjects: 947

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 947
Study: 36700520

Group type: EXPERIMENTAL
Intervention: Short-term prophylactic dose anticoagulation
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Long-term therapeutic dose oral anticoagulation
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Long-term antiplatelet therapy
Number of subjects: 1491

Group type: COMPARATOR
Intervention: Long-term cilostazol
Number of subjects: 1491
Study: 36700571

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program with telecoaching (weekly phone calls from a physiotherapist)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Home-based pulmonary rehabilitation program without telecoaching
Number of subjects: 42
Study: 36700700

Group type: EXPERIMENTAL
Intervention: Survivors of poor-grade aSAH after 6 months
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Survivors of poor-grade aSAH after 12 months
Number of subjects: 250
Study: 36700705

Group type: EXPERIMENTAL
Intervention: i-FACTOR
Number of subjects: 220

Group type: COMPARATOR
Intervention: Local autograft
Number of subjects: 220
Study: 36700738

Group type: EXPERIMENTAL
Intervention: Open shunt group (Codman Certas Plus valve set at 4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo group (Codman Certas Plus valve set at 8)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Open shunt group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 18
Study: 36700734

Group type: EXPERIMENTAL
Intervention: BI 425809 25 mg once daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Warfarin and digoxin alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 13
Study: 36700770

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 36700853

Group type: EXPERIMENTAL
Intervention: Gene expression changes in fetal brain samples with biallelic pathogenic variants in HEXA
Number of subjects: 0
Study: 36700928

Group type: EXPERIMENTAL
Intervention: Nondiffractive EDOF IOL
Number of subjects: 52

Group type: COMPARATOR
Intervention: Trifocal IOL
Number of subjects: 52
Study: 36701139

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU)
Number of subjects: 2259

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg)
Number of subjects: 2259

Group type: EXPERIMENTAL
Intervention: Both vitamin D3 and calcium
Number of subjects: 2259
Study: 36701146

Group type: EXPERIMENTAL
Intervention: Plasma inflammatory biomarkers (IL-6, sTNF-αR2, hsCRP) in the highest quintile of inflammation
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Plasma inflammatory biomarkers (IL-6, sTNF-αR2, hsCRP) in the lowest quintile of inflammation
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Inflammatory biomarkers and celecoxib intervention
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Higher inflammation after diagnosis
Number of subjects: 1494
Study: 36701184

Group type: EXPERIMENTAL
Intervention: Over-the-counter pain and indigestion medications
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Indigestion medications
Number of subjects: 273
Study: 36701271

Group type: EXPERIMENTAL
Intervention: Acculturative stress
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Sleep disturbance (mediator)
Number of subjects: 400
Study: 36701331

Group type: EXPERIMENTAL
Intervention: Persistently enlarged genital hiatus (GH)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Stably normal GH
Number of subjects: 81
Study: 36701401

Group type: COMPARATOR
Intervention: Quitting Immediately (QI)
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Quitting Progressively (QP)
Number of subjects: 1571
Study: 36701531

Group type: EXPERIMENTAL
Intervention: Mindful yoga intervention (MYI) as add-on to treatment as usual (TAU)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 171
Study: 36701604

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 200
Study: 36701613

Group type: EXPERIMENTAL
Intervention: Fasting for 6 or more hours
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral intake ('fed') within 2 hours of the test
Number of subjects: 200
Study: 36701619

Group type: EXPERIMENTAL
Intervention: Heavier-weight polypropylene mesh
Number of subjects: 339

Group type: COMPARATOR
Intervention: Lightweight polypropylene mesh
Number of subjects: 339
Study: 36701620

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training using a motion-based digital therapeutic device
Number of subjects: 363

Group type: COMPARATOR
Intervention: Standard home pelvic floor muscle training program
Number of subjects: 363
Study: 36701635

Group type: EXPERIMENTAL
Intervention: Recovery expectancy (measured through preoperative survey)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: High recovery expectancy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Actual recovery (measured at postoperative weeks 2 and 6)
Number of subjects: 174
Study: 36701651

Group type: EXPERIMENTAL
Intervention: OBI-999 at 1.2 mg/kg every 21 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: OBI-999 at 1.6 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: OBI-999
Number of subjects: 15
Study: 36701676

Group type: EXPERIMENTAL
Intervention: Allergen Immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard care not specified)
Number of subjects: 0
Study: 36701797

Group type: EXPERIMENTAL
Intervention: Optimized acute treatment of migraine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36702070

Group type: EXPERIMENTAL
Intervention: Neratinib dose escalation over the first 2 weeks (DE1)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Colestipol + loperamide (CL)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Neratinib dose escalation over the first 4 weeks (DE2)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Budesonide + loperamide (BL)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Loperamide (L)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Colestipol + loperamide as needed (CL-PRN)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Neratinib with proactive management
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Neratinib treatment
Number of subjects: 563
Study: 36702138

Group type: EXPERIMENTAL
Intervention: G-CSF, decitabine, and busulfan-cyclophosphamide conditioning
Number of subjects: 202

Group type: COMPARATOR
Intervention: busulfan-cyclophosphamide conditioning
Number of subjects: 202
Study: 36702146

Group type: EXPERIMENTAL
Intervention: Tezepelumab (210 mg every 4 weeks)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 36702329

Group type: EXPERIMENTAL
Intervention: Mivavotinib 60-120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity
Number of subjects: 124
Study: 36702499

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgical thalamotomy
Number of subjects: 27
Study: 36702566

Group type: EXPERIMENTAL
Intervention: rtCGM with alerts (n=127)
Number of subjects: 254

Group type: COMPARATOR
Intervention: is-rtCGM (switched from isCGM without alerts to rtCGM with alerts; n=119)
Number of subjects: 254